The expansion is part of Governor DeSantis' allocation of additional doses of the Moderna vaccine to be administered to individuals ages 65 and older.
Eligible individuals can make appointments using the online reservation system at publix.com/covidvaccine, with vaccinations starting Thursday, Jan. 14.
The announcement brings the total number of Publix pharmacies offering COVID-19 vaccinations to 105 in 12 counties.
Vaccinations are provided to eligible individuals, by appointment only, while supplies last, and at no cost to the individual. Customers with health insurance will need to bring their insurance card to their scheduled appointment.
Customers without health insurance will need to provide their driver's license or Social Security number.
This expansion comes after the company received and distributed its first shipment of vaccines.
Publix continues to communicate with the state of Florida and the other six states in its operating area to provide COVID-19 vaccinations as part of their distribution efforts.
Publix, the largest employee-owned company in the US with more than 225,000 associates, currently operates 1,264 stores in Florida, Georgia, Alabama, Tennessee, South Carolina, North Carolina and Virginia.
European Commission approves GSK's Arexvy for adults aged 18 and over
PhotonPharma adds Dr. William Warren to board
GSK wins European Commission approval for Shingrix prefilled syringe
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Avetra unveils site-centric CRO operating model
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s